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was 93.3% at 19 months and 81.6% estimated at ﬁve years. Disease-free survival at mean follow-up was 89.7% and 74.4% 5 years.
Rectal, urinary and vaginal late toxicity was moderate (CTC grade 2: 5.5%, 5.5% and 17.5% respectively). OS was signiﬁcantly
worse in patients with para-aortic disease compared with those without disease (p<0.000) and in patients with prolonged (>8
weeks) radiation treatment (p=0.022). 25 patients complete QLQ C30, QLQ CX24 and IFSF as measures of quality of life and sexual
function with mean scores of 3.45/4 and 3.07/4 although IFSF mean score was 1.84/5.
Conclusions. Laparoscopic extraperitoneal aortic lymphadenectomy is a feasible procedure, which identify patients with para-
aortic disease tailoring their treatment. The addition of para-aortic external radiation therapy seems to be well tolerated by the
patients, with apparently no inﬂuence in quality of life.
http://dx.doi.org/10.1016/j.rpor.2013.03.242
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Introduction. The uterine cervical carcinomas remain a health problem with poor survival rates and low rates of local and dis-
tant control. The use of 3D conformal radiotherapy (RTC3D) associated with concomitant chemotherapy (CT) utilizes a same
therapeutic approach all the advantages of a multimodal treatment.
Objective. To perform a descriptive analysis end, a phase II study with QT induction RTC3D/QT and BRT/surgery effort.
Material and methods. Between February 1999 and April 2009 a total of 139 patients diagnosed with uterine cervical carcinoma
were included. The mean age was 58 years (range 29–78). Stage distribution was: IB2 (5.75%), IIA (5.03%), IIB (40.3%), IIIA (2.9%),
IIIB (31.6%), IV (7.91%) and no visceral IVB (6.47%). -Scheme of chemotherapy: a) A CT cycle induction Cisplatin 75mg/m2 and
750mg/m2 Tegafur. Concomitant CT: Cisplatin 25mg/m2 weekly and Tegafur 450mg/m2. - Scheme of Radiotherapy: Virtual
simulation and 3-D planning. The total dose was 45–50.4Gy.
Results. A total of 139 patients were performed until December 2012. With a median follow-up of 110 months (range 46–168
months) are still Alive (49.6%), Exitus (50.4%). Overall survival: by stages: IB2 (62.5%), IIA (85.7%), IIB (67.8%), IIIA (75%), IIIB (27.2%),
IV A (36%), IV B (11.1%). Responses: CR 96 (69.1%), PR 31 (22.3%), ED1 patient (0.7%), PD 1 patient (0.7%), NA (7.2%). Proﬁle of
Recurrence: local (38), regional (37), remote (22), para-aortic note 9. Severe acute toxicity: hematologic 7.9%, gastrointestinal
5.7%, gynecological 2.9%, vascular 4.3%, other 2.9%. Severe chronic toxicity: retroperitoneal ﬁbrosis 4.3%, gastrointestinal 2.9%,
urological 1.4%, other 2.4%. Exitus: 4 patients: In patients surviving longer submitted 9 secondary neoplasms.
Conclusions. The survival for stages IB2 to IIIA is high of 62.5 to 85.7%. In IIIB to IVA is around 36% and 11.1% and the of percetntage
loco – regional recurrence is high. Toxicity is manageable.
http://dx.doi.org/10.1016/j.rpor.2013.03.243
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Purpose. To analyze retrospectively the outcome of patients with cervical cancer treated with external beam radiotherapy (EBR)
and high-dose-rate (HDR) brachytherapy.
Methods and materials. From November 2002 to November 2012, 89 patients with FIGO Stages IB to IVB were treated. The mean
patient age was 53 years. Most frequently used EBR dose to the whole pelvis (with or without paraortic nodes included) was 45Gy
in 25 fractions. Parametrial or bulky lymph node (LN) boost was performed in 11.2% of patients. Brachytherapy with HDR was
performed during EBR or following its completion with ﬁve weekly fractions of 5.5–6Gy to point A. Within the EBR, 79 of the 89
patients (88%) received concomitant chemotherapy (weekly cisplatin: 52 patients or taxol: 27 patients). Patient age, tumor stage,
LN metastases, para-aortic LN sampling and histology were variables analyzed for survival and local control; whereas, doses at
organ risk were variables for analyzing late toxicity. Initially plain X-ray ﬁlm simulation was the standard of care, but further in
time, CT planning was performed. Doses at the rectum and bladder ICRU reference points were calculated for the ﬁrst, and D2cc
bladder, rectum and sigmoid were calculated for the second.
Results. Median follow-up time was 33 months. Three patients had stage I disease (3.3%); 44 stage II disease (49.5%); 32 stage III
disease (36%) and 10 stage IV (11.2%). Five patients (6%) suffered local failure, 5 pelvic nodal failure (6%) and 21 (25%) distant
metastases. Overall survival, disease-free survival, and loco-regional control at 5 years was 68.8%, 59.2%, and 81.9% respectively.
